Immunohistochemistry results demonstrated that ovarian cancer patients with positive expression of BMP-2, BMPRIB, and BMPRII exhibited remarkably higher five-year survival rates and average survival rates than patients with negative expression of BMP-2, BMPRIB, and BMPRII. The gene discussed is BMPR2; the disease is ovarian cancer.